PMID- 36455142
OWN - NLM
STAT- MEDLINE
DCOM- 20230214
LR  - 20230214
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 29
IP  - 2
DP  - 2023 Mar
TI  - Analysis of the Mechanism of Action of Kushen in the Treatment of Tuberculosis 
      Based on Network Pharmacology.
PG  - 155-161
LID - AT7586 [pii]
AB  - CONTEXT: Drug-resistant tuberculosis (TB), especially multidrug-resistant TB, has 
      continued to increase and pan-drug-resistant TB and even fully drug-resistant TB 
      have emerged, bringing great challenges to the treatment of TB. Development of 
      new, safe, and effective antituberculosis drugs is an urgent need. OBJECTIVE: The 
      study intended to evaluate the use of the network pharmacology method to 
      comprehensively and systematically analyze the network relationship of Kushen's 
      main components, targets, and signaling pathways, aiming to provide new ideas and 
      clues for an in-depth study of the mechanism of Kushen's main components in the 
      treatment of pulmonary TB. DESIGN: The research team performed a Network 
      pharmacology analysis. SETTING: The study took place in the Department of 
      Respiratory and Critical Care Medicine at the Third People's Hospital of Yichang 
      City in Yichang, Hubei, China. OUTCOME MEASURES: The research team: (1) screened 
      Kushen's active ingredients and related targets using the Traditional Chinese 
      Medicine System Pharmacology (TCMSP) database and analysis platform; (2) used the 
      GeneCards database and the Online Mendelian Inheritance in Man (OMIM) database to 
      search for disease targets, (3) connected the active ingredient's targets to the 
      disease targets to obtain predictive targets for Kushen to act against TB, (4) 
      used the STRING database to construct a protein-protein interaction (PPI) network 
      map, (5) used the Database for Annotation, Visualization and Integrated Discovery 
      (DAVID) to subject the intersecting genes to gene ontology (GO) and Kyoto 
      Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, and (6) used the 
      TCMSP and Protein Data Bank (PDB) databases to dock the active ingredients with 
      target-protein molecules. RESULTS: The research team found 45 active ingredients 
      for Kushen and 177 target-protein genes related to active ingredients. The PPI 
      network map of the Kushen-TB targets and found that the top 10 targets of Kushen 
      were: (1) mitogen-activated protein kinase 8 (MAPK8); (2) protein kinase B 
      (AKT1); (3) MAPK1, (4) estrogen receptor 1 (ESR1), (5) rel avian 
      reticuloendotheliosis viral oncogene homolog A (RELA), (6) interleukin-6 (IL6), 
      (7) MYC proto-oncogene, basic helix-loop-helix (bHLH) transcription factor MYC), 
      (8) retinoid X receptor alpha (RXRA), (9) FOS proto-oncogene activator protein 1 
      (AP-1) transcription factor subunit (FOS), and (10) JUN proto-oncogene AP-1 
      transcription factor subunit (JUN). The KEGG analysis suggested that Kushen can 
      intervene in TB through the hypoxia-inducible factor 1 (HIF-1) signaling pathway. 
      CONCLUSIONS: The network pharmacology analysis showed that Kushen's active 
      ingredients can play a role in the treatment of TB through the HIF-1 signaling 
      pathway.
FAU - Lin, Min
AU  - Lin M
FAU - Zhou, Huan
AU  - Zhou H
FAU - Li, Rong
AU  - Li R
FAU - Quan, Li-Li
AU  - Quan LL
FAU - Jin, Zhu
AU  - Jin Z
FAU - Tong, Xiao-Wei
AU  - Tong XW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - IYR6K8KQ5K (kushen)
RN  - 0 (Transcription Factor AP-1)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Humans
MH  - Network Pharmacology
MH  - Transcription Factor AP-1
MH  - *Tuberculosis
MH  - *Tuberculosis, Multidrug-Resistant
MH  - Medicine, Chinese Traditional
MH  - *Drugs, Chinese Herbal/pharmacology/therapeutic use
EDAT- 2022/12/02 06:00
MHDA- 2023/02/15 06:00
CRDT- 2022/12/01 15:23
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2023/02/15 06:00 [medline]
PHST- 2022/12/01 15:23 [entrez]
AID - AT7586 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2023 Mar;29(2):155-161.